Latest Revenue Guidance News

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Amaero Ltd has updated its FY2026 financial guidance, forecasting revenue between A$30 million and A$35 million; a staggering 800%-900% increase year-over-year; and announced a A$50 million capital raise to expand production capacity and reduce costs.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Fluence Corporation Limited reported a robust 64.7% revenue increase to $33.1 million in H1 2025, driven by the Ivory Coast Addendum project and a strategic pivot to high-margin solutions. The company improved EBITDA to a positive $0.1 million and reduced fixed costs, signaling progress in its operational realignment.

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.

FINEOS Corporation Holdings PLC reports solid half-year growth with rising subscription revenue and improved margins, while navigating currency challenges. The company remains confident in achieving positive free cash flow for FY25 and advancing its AI and cloud strategies.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.